gptkbp:instance_of
|
gptkb:immunotherapy
|
gptkbp:administered_by
|
oral tablet
|
gptkbp:approves
|
gptkb:2007
gptkb:China
gptkb:Vietnam
other Southeast Asian countries
|
gptkbp:atccode
|
P01 BE02
|
gptkbp:available_on
|
generic drug
|
gptkbp:brand
|
gptkb:Piperaquine
|
gptkbp:can_be_combined_with
|
gptkb:dihydroartemisinin
|
gptkbp:casnumber
|
100912-21-4
|
gptkbp:category
|
gptkb:C
|
gptkbp:chemical_formula
|
C19 H22 Cl2 N2 O
|
gptkbp:clinical_trial
|
Phase II
Phase III
|
gptkbp:clinical_use
|
second-line treatment
first-line treatment
|
gptkbp:contraindication
|
severe liver disease
severe renal impairment
hypersensitivity to piperaquine
|
gptkbp:developed_by
|
Chinese pharmaceutical companies
|
gptkbp:dissolved
|
poorly soluble in water
|
gptkbp:duration
|
3 days
7 days
|
https://www.w3.org/2000/01/rdf-schema#label
|
piperaquine
|
gptkbp:interacts_with
|
antacids
certain antibiotics
antifungal medications
|
gptkbp:is_effective_against
|
high against Plasmodium falciparum
high against Plasmodium vivax
|
gptkbp:is_often_used_in
|
gptkb:artesunate
|
gptkbp:lifespan
|
approximately 10 days
|
gptkbp:marketed_as
|
gptkb:Piperaquine_phosphate
|
gptkbp:mechanism_of_action
|
inhibits heme polymerization
|
gptkbp:metabolism
|
liver
|
gptkbp:packaging
|
blister packs
|
gptkbp:provides_guidance_on
|
WHO recommendations
CDC guidelines
|
gptkbp:research_focus
|
pharmacokinetics
combination therapies
safety profile
malaria resistance
|
gptkbp:rounds
|
urine
|
gptkbp:safety_measures
|
required during treatment
|
gptkbp:side_effect
|
gptkb:anemia
dizziness
headache
nausea
vomiting
thrombocytopenia
leukopenia
QT prolongation
|
gptkbp:storage
|
room temperature
|
gptkbp:used_for
|
treatment of malaria
|
gptkbp:bfsParent
|
gptkb:artemisinin-based_therapies
|
gptkbp:bfsLayer
|
7
|